Biotechnology and patentability: navigating unchartered waters in Australia and the US
The debate over the patentability of isolated DNA has raged around the world. Tania Obranovich compares the two Myriad decisions from the highest courts in Australia and the US and explains how the Australian decision has called into question what had long been thought of as a fundamental pillar of Australian patent law
Myriad's BRCA patents, which claim both breast cancer diagnostic methods and the isolated BRCA DNA molecules, have courted significant controversy both in Australia and the US in recent years. Extensive judicial consideration in relation to the patent eligibility of isolated...
Please
log in to read the rest of this article.
New to Managing Intellectual Property? Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Already registered?
Please make sure you log in to read the rest of the article.
Log in
Join us now
Gain FREE access to up to five free articles when you register now. Join here